The Fenlix Motor — Computational Characterization of B01_noEt as a Dual DYRK1A/CDK5 Inhibitor Candidate
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
DESCRIPTION Perhaps the change of a single atom in a drug could change a life. This work is not about autism statistics. It focuses on a single molecule, a precise mechanism, and a concrete, testable starting point for experimental chemistry. We introduce B01_noEt, a minimal structural modification of Roscovitine—a compound with over 20 years of human clinical history—as a candidate dual DYRK1A/CDK5 inhibitor. Both kinases are master regulators of neurodevelopment, whose dysfunction converges in autism spectrum disorder. Key Findings DualSel = 1.250 — quantified selectivity over toxic off-targets CDK2 structurally avoided (score: 3.117) via steric clash with PHE82 Crystallographic anchors: GLU291 (DYRK1A) · GLN85 (CDK5) Blood–brain barrier penetration inherited from the parent scaffold Methodology SO(3) rotational sampling — 4096 orientations per ligand–receptor pair Validated across 90 human kinases 74% crystallographic convergence Executed entirely on accessible mobile hardware (cost: $0) Accessibility This manuscript is intentionally self-contained.A physician, researcher, or parent seeking answers can read it end-to-end without requiring prior literature. Code & License Source code is available under thePolyForm Noncommercial License 1.0.0 (International) Academic use: unrestricted Commercial use: requires written authorization Contact Andrés Sebastián Pirolo andrespirolo@gmail.com
Fields of Study & Subjects
Computational Drug Discovery Methods
Protein Degradation and Inhibitors
Protein Kinase Regulation and GTPase Signaling
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 27 March 2026
- Language
- EN
- Document type
- Preprint